Human Papillomavirus Infections and Vulvar Disease Development
- 1 June 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 18 (6), 1777-1784
- https://doi.org/10.1158/1055-9965.epi-09-0067
Abstract
Background: We describe the prevalence of 14 common types [human papillomavirus (HPV)-6/11/16/18/31/33/35/39/45/51/52/56/58/59] in vulvar intraepithelial neoplasia grades 1 to 3 (VIN 1-3) and HPV genotype–specific infection in relation to the development of VIN 1-3. Methods: Data were analyzed from women enrolled in the placebo arms of three randomized double-blind trials. Anogenital examinations, including collection of labial/vulvar/perineal/perianal swabs, occurred at day 1 and every 6 to 12 months through 48 months. Lesions that were possibly, probably, or definitely HPV related or of unknown etiology were biopsied. Biopsies and swabs were HPV typed. Biopsies were read for endpoint determination (VIN 1-3) by up to four pathologists. Results: Incident infection with HPV-16 was the most common (6.0/100 person-years). The mean time from incident infection to the development of VIN 1-3 was 18.5 months (95% confidence interval, 13.4-23.6). HPV-6 or -11 was observed in 64.5% of VIN 1 and 29.0% of VIN 2/3, whereas HPV-16 was observed in 6.5% of VIN 1 and 64.5% of VIN 2/3. Conclusion: A vaccine that includes both low- and high-risk types could prevent more than half of VIN 1-3 lesions, including the precursor lesions to HPV-related vulvar carcinoma. Understanding the incidence and duration of vulvar HPV infection and risk for progression to VIN 1-3 may inform therapeutic decisions for vulvar disease and mathematical models that assess the cost-effectiveness of vaccination. (Cancer Epidemiol Biomarkers Prev 2009;18(6):1777–84)This publication has 29 references indexed in Scilit:
- Distribution of human papillomavirus genotypes in invasive squamous carcinoma of the vulvaLaboratory Investigation, 2008
- Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesVaccine, 2008
- Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenInfectious Agents and Cancer, 2007
- Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle VaccinesClinical and Vaccine Immunology, 2007
- Effect of Human Papillomavirus Vaccines on Vulvar, Vaginal, and Anal Intraepithelial Lesions and Vulvar CancerObstetrics & Gynecology, 2006
- Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasiaGynecologic Oncology, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Vulvar Intraepithelial NeoplasiaObstetrics & Gynecology, 2005
- Multi-Attribute Health Status Classification SystemsPharmacoEconomics, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958